Demographic information: safety patient group (n = 226)
| Placebo (n = 57) | Tedisamil twice daily | |||||
|---|---|---|---|---|---|---|
| 50 mg (n = 55) | 100 mg (n = 60) | 150 mg (n = 54) | Total (n = 226) | |||
| Age (years) | 59.7 (6.5) | 60.5 (7.4) | 61.7 (6.8) | 60.7 (7.3) | 60.7 (7.0) | |
| Sex (n (%)) | ||||||
| Male | 56 (98.2) | 50 (90.9) | 54 (90.0) | 50 (92.6) | 210 (92.9) | |
| Female | 1 (1.8) | 5 (9.1) | 6 (10.0) | 4 (7.4) | 16 (7.1) | |
| Weight (kg) | ||||||
| Male | 80.3 (12.4) | 81.3 (9.2) | 83.0 (11.0) | 79.8 (11.7) | 81.1 (11.2) | |
| Female | 79.0 | 61.6 (14.8) | 75.3 (10.8) | 69.8 (14.2) | 69.9 (13.3) | |
| Height (cm) | ||||||
| Male | 173 (9) | 171 (8) | 173 (6) | 171 (15) | 172 (10) | |
| Female | 170 (-) | 159 (6) | 161 (7) | 160 (3) | 161 (6) | |
Values are mean (SD) except where stated.